TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06109454

Intervention type: DRUG
Intervention: Huaier granule
Description: The subjects voluntarily gave up postoperative adjuvant therapy, including chemotherapy, targeted therapy, immunotherapy, and radiation therapy, and agreed to take Huaier granules.The subjects took Huaier granules orally, one bag (10g) per time, three times a day. Until the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, or when the researcher determines that there is no further benefit, whichever occurs first. Please refer to the drug manual for specific usage. It is recommended that patients start taking Huaier granules 1-2 weeks after surgery.

Intervention type: OTHER
Intervention: Control
Description: The subjects received standard platinum dual drug chemotherapy.The subjects were treated with carboplatin injection (300mg/m2, intravenous injection, first day) combined with pemetrexed disodium (pathological type: adenocarcinoma, intravenous injection, 500mg/m2) or albumin bound paclitaxel (pathological type: squamous cell carcinoma, 260mg/m2, intravenous injection, first day) every three weeks, with a maximum of four cycles.
Study: NCT04802018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinical decision support system based on non-invasive multimodal monitoring
Description: Non-invasive multimodal vital signs monitoring with the wearabl to monitor for a period of 10 days after the date of positive diagnosis to COVID-19. The device will be linked to the Home App, which will allow the sending of temperature, HR and RR data to the server every 15 minutes a day and the notification of symptoms by the patient three times a day.
Study: NCT05800236

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gastrectomy
Description: Patients operated on for curative purposes at the Bordeaux University Hospital for gastric adenocarcinoma of any type or stage and Collection of two venous blood tubes
Study: NCT06394206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialized Unit
Description: The participant will be visited every three months for one year

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Follow-Up
Description: The participant will be visited as usual, it means they will be visited at Digestive Consultation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Follow-Up
Description: The participant will be visited as usual, it means they will be visited at Digestive Consultation
Study: NCT04661371

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Method of operation~1. Surgery was started under general anesthesia~2. A trocar of 10 mm was placed on the navel, 5 mm under the blade, and 5 mm trocar was placed on the right upper abdomen.~3. Pneumoperitoneum was performed using CO2 gas in the abdominal cavity.~4. Dissection started from Calot's triangle and the operation was performed by retrograde cholecystectomy.~5. The excised gallbladder was placed in a laparoscopic pocket and extracted through the umbilicus.~6. The trocar was removed and the skin was sutured~On the 1st day after surgery, hematology, blood chemistry, urine, blood clotting, and chest x-rays were performed. (Inspection and treatment were performed according to the current clinical pathway of gallbladder surgery)
Study: NCT05143528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib BE 84mg
Description: 84 mg capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib BE 112 mg
Description: 112 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule
Study: NCT06132724

Intervention type: OTHER
Intervention: Signal acquisition
Description: Synchronized signals from cardiac, respiratory and movements non invasive measurements.~One acquisition is 20 minutes long, and each subject participate to two sessions, separated by 1 to 15 days.
Study: NCT06388421

Intervention type: OTHER
Intervention: Prospective study assessments
Description: Patients will complete prospective assessments at 6- and 12-month intervals for up to 5 years. There will be 1 check in at the first 3 months of enrollment. Follow up visits will include a ±45 day visit window. If an assessment is performed within 45 days of the visit window as part of the patient's standard of care, those values will be used in place of a prospective assessment.

Intervention type: OTHER
Intervention: Prospective study assessments
Description: Patients will complete prospective assessments at 6- and 12-month intervals for up to 5 years. There will be 1 check in at the first 3 months of enrollment. Follow up visits will include a ±45 day visit window. If an assessment is performed within 45 days of the visit window as part of the patient's standard of care, those values will be used in place of a prospective assessment.
Study: NCT06790745

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural blood patch
Description: Patients will receive epidural blood patch injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma rich fibrin epidural injection by Racz catheter
Description: Patients will receive plasma rich fibrin injection by Racz catheter
Study: NCT04662112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NASOX
Description: Oxalipatin 60 mg/m2 IV (2 h infusion) on Day 1, every 2 weeks Nal-IRI 50-60 mg/m2 IV (FBE, 90 min infusion) on Day 1, every 2 weeks S-1 40mg/m2 oral twice daily on Day 1-7, every 2 weeks
Study: NCT06791057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyspnea Intervention
Description: Brief behavioral intervention for dyspnea management that includes three nurse-led sessions focused on psychoeducation, behavioral techniques for managing acute breathlessness, and relaxation training for reducing physiological stress as well as a digital health app to reinforce practice of breathing skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Patients will receive educational materials on the management of symptoms of lung cancer and its treatment as well as any usual care for dyspnea deemed appropriate by the clinical team.
Study: NCT06792435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW27011
Description: Eligible patient(s) in each dose cohort will receive the assigned XNW27011 dose administration every 3 weeks (Q3W, cycle) until intolerable toxicity, progression of the disease without clinical benefit, or withdrawal of informed consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW27011
Description: Group A: Gastric/gastroesophageal junction adenocarcinoma with CLDN18.2 expression, tentatively expand with 3.6, 3.0, 2.4 mg/kg. Group B: Pancreatic adenocarcinoma with CLDN18.2 expression, tentatively expand with 3.6, 3.0, 2.4 mg/kg. Group C: Ovarian cancer with CLDN18.2 expression, tentatively expand with 3.6, 3.0, 2.4 mg/kg. Group D: Other tumors with CLDN18.2 expression, including but not limited to esophagus adenocarcinoma, lung cancer, colorectal cancer, and biliary tract cancer,tentatively expand with 3.6, 3.0, 2.4 mg/kg.
Study: NCT06788834

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation Program
Description: A tailored intervention will be prescribed if specific physical, nutritional or psychological impairments will be identified during the assessment phase.~Based on the data obtained during the multimodal assessment, different domains and levels of care will be prescribed, focusing on exercise training, and/or nutrition optimization, and/or distress-coping techniques. Different combinations of three domains will be utilized to maximize their synergistic anabolic effects. The duration of the program will be set at a minimum of three weeks.
Study: NCT05059041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dilated Refraction
Description: The dilated refraction will be a trial spectacle frame composed of lenses based upon a spectacle prescription determined from dilated measures of the eye using a wavefront aberrometer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dilated Refraction
Description: The dilated refraction will be a trial spectacle frame composed of lenses based upon a spectacle prescription determined from dilated measures of the eye using a wavefront aberrometer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Dilated Refraction
Description: The non-dilated refraction will be a trial spectacle frame composed of lenses based upon a spectacle prescription determined from non-dilated measures of the eye using a wavefront aberrometer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Dilated Refraction
Description: The non-dilated refraction will be a trial spectacle frame composed of lenses based upon a spectacle prescription determined from non-dilated measures of the eye using a wavefront aberrometer.
Study: NCT04708418

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLP-encapsulated TLR9 Agonist CMP-001
Description: Given SC or intratumorally
Study: NCT06783049

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cerebrovascular Disease Secondary Prevention Smart Management System
Description: The continuous post-discharge intervention for patients was conducted using the Cerebrovascular Disease Secondary Prevention Smart Management System. This system, integrated with a WeChat-based applet, records patients' basic information and connects with mobile IoT devices such as blood pressure monitors and glucose meters. This allows patients to self-monitor their risk factors post-discharge. Based on international guidelines, high-level evidence, and the clinical expertise of cerebrovascular specialists, a comprehensive clinical decision-making tree was developed. This serves as the foundation for an AI feedback system that provides intelligent feedback on risk factor control and predicts the risk of recurrence.
Study: NCT06786936

Intervention type: DRUG
Intervention: Secukinumab
Description: Initial dosing of Secukinimab at week 0, 1, 2, 3, 4 and maintenance doses will be determined by the standard care team. This will be 150mg or 300mg. This will be administered by the study team once confirmed and randomisation has occurred for secukinimab/ placebo allocation.

Intervention type: DRUG
Intervention: Bimekizumab
Description: Initial dosing of bimkizumab at week 0 \& 4 and maintenance doses will be determined by the standard care team. This will be 160mg or 320mg. This will be administered by the study team once confirmed and randomisation has occurred for bimekizumab/ placebo allocation.

Intervention type: DRUG
Intervention: Ixekizumab
Description: Initial dosing of Ixekizumab at week 0 \& 4 or week 0, 2 \& 4, maintenance doses will be determined by the standard care team. The initial dose will be 160mgs then 80mg dose will either be given 2 or 4 weekly. This will be administered by the study team once confirmed and randomisation has occurred for Ixekizumab/ placebo allocation.

Intervention type: DRUG
Intervention: Placebo
Description: Sodium chloride 0.9% for injection will be used as a placebo. A 1ml volume will be drawn up into a suitable sized syringe and labelled in accordance with standard practice at site. The dose will be administered as a subcutaneous injection in line with the Secukinumab/ Bimekizumab/ Ixekizumab dosing regimen. No dose adjustments are permitted.
Study: NCT06321562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TimoD implant
Description: Consists of 1 TimoD implant administration in the study eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TimoD implant
Description: Consists of 1 TimoD implant administration in the study eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TimoD implant
Description: Consists of 1 TimoD implant administration in the study eye

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injector system
Description: This is a CE-marked injector intended for intraocular lens (IOL) delivery. In this study, the injector is used as anintraocular implant injection system outside of its scope of intended use.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injector system
Description: This is a CE-marked injector intended for intraocular lens (IOL) delivery. In this study, the injector is used as anintraocular implant injection system outside of its scope of intended use.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injector system
Description: This is a CE-marked injector intended for intraocular lens (IOL) delivery. In this study, the injector is used as anintraocular implant injection system outside of its scope of intended use.
Study: NCT06784752

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [^177Lu]Lu-DOTA-TATE
Description: \[\^177Lu\]Lu-DOTA-TATE will be administered 4 times during treatment period with frequency of every 8 weeks (Q8W)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide LAR
Description: Octreotide LAR will be administered Q8W when co-administered with \[\^177Lu\]Lu-DOTA-TATE in the investigational arm followed by Q4W.~In the control arm Octreotide LAR will be administered Q4W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR
Description: Octreotide LAR will be administered Q8W when co-administered with \[\^177Lu\]Lu-DOTA-TATE in the investigational arm followed by Q4W.~In the control arm Octreotide LAR will be administered Q4W.
Study: NCT06786832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for persistent fatigue
Description: The treatment is based on a treatment manual that has previously been evaluated in several randomized controlled trials for persistently fatigued patients with various types of chronic somatic disorders (primarily in specialized healthcare settings).~In this trial we have translated the treatment manual to Swedish and adopted it for implementation in a Swedish primary care setting. The treatment format is blended, meaning that the treatment is administered both via an online platform (where the participant can communicate with the therapist through asynchronous text-messages) and via face-to-face therapy sessions with the therapist.

Intervention type: OTHER
Group type: OTHER
Intervention: Care as usual
Description: Since there are no standardized, structured care programs and guidelines for the patient group, CAU may include a broad variety of psychosocial support, psychological treatment, physiotherapy, occupational therapy, pharmacological treatment, follow-up within specialist healthcare, and/or follow-up by general practitioners. An important aim of the project is to carefully map the content and scope of the care offered to patients in the study within the framework of CAU.
Study: NCT05025397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danavorexton
Description: Danavorexton intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danavorexton
Description: Danavorexton intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danavorexton
Description: Danavorexton intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danavorexton
Description: Danavorexton intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danavorexton Placebo
Description: Danavorexton placebo-matching intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danavorexton Placebo
Description: Danavorexton placebo-matching intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danavorexton Placebo
Description: Danavorexton placebo-matching intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danavorexton Placebo
Description: Danavorexton placebo-matching intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol intravenous bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol intravenous bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol intravenous bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol intravenous infusion.
Study: NCT06098911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MI varnish
Description: delivers a powerful dose of fluoride, with the added booster effect of the calcium and phosphate ions through its patented Recaldent™ technology. High initial fluoride release. Minimizes tooth sensitivity and strengthens enamel. Neutral pH of 6,6 enhances enamel and dentin acid resistance and inhibits demineralization
Study: NCT05809050

Intervention type: DIAGNOSTIC_TEST
Intervention: BM aspirate
Description: Bone Marrow aspiration \& Examination

Intervention type: DIAGNOSTIC_TEST
Intervention: BM aspirate
Description: Bone Marrow aspiration \& Examination
Study: NCT05898776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung transplantation after 10°C donor lung preservation
Description: When suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to 10°C preservation will be stored, transported and preserved in the X°Port Lung Transport Device (Traferox Technologies Inc.) until implant with a maximum time of 12 hours between the donor and recipient surgeries.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung transplantation after standard ice cooler donor lung preservation
Description: When suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to standard preservation will be will be stored, transported and preserved in an ice cooler (\~4°C, standard of care) until implant with a maximum time of 6 hours between the donor and recipient surgeries.
Study: NCT05586503

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG-gated CTAs
Description: ECG-gated CTAs will be performed instead of static CTAs comparing to standard of care
Study: NCT06383247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: The stimulations were performed by MagStim Rapid2.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: The stimulations were performed by MagStim Rapid2.
Study: NCT05402163

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive DBS
Description: aDBS vs cDBS
Study: NCT04758780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-TLX250 PET/CT
Description: Pretherapeutic 89Zr-TLX250 PET/CT
Study: NCT06789237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weighted blanket
Description: Participants will be covered with a weighted blanket for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weighted blanket
Description: Participants will be covered with a weighted blanket for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weighted blanket
Description: Participants will be covered with a weighted blanket for 30 minutes

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: non-weighted blanket
Description: Participants will be covered with a sham non-weighted blanket for 30 minute
Study: NCT06787885

Intervention type: DRUG
Group type: OTHER
Intervention: Levofloxacin + clindamycin
Description: Group 1

Intervention type: DRUG
Group type: OTHER
Intervention: Levofloxacin + cefipime
Description: Group 2

Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin + meronam
Description: Group 3
Study: NCT06786156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pecha Kucha Education
Description: After the first interviews, the participants will be given face-to-face training to count fetal movements in the first stage. The training will last 30-45 minutes. The training content includes a comfortable environment and a suitable position for pregnant women, how to count and what to look for before counting fetal movements. Then, the training will be sent to the pregnant women via WhatsApp. A form will be given to count the fetal movements, and training will be applied using the Pecha Kucha method using smartphones once a week for 4 weeks. Pecha kucha is a presentation method developed to attract and maintain the attention of the audience throughout a series of different presentations. Pecha kucha (P-K), derived from the word meaning chat in Japanese, is to help present creative works with visual images. Pecha kucha training includes position, how to count and what to look for before counting fetal movements. This training will be delivered via WhatsApp with a practical presenta